View Older Stories View More Recent Stories

Dec 7, 2020 06:35AM Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Dec 7, 2020 06:35AM Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
Dec 6, 2020 03:00PM Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
Dec 6, 2020 12:30PM Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
Dec 5, 2020 12:30PM Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
Dec 5, 2020 10:00AM New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma
Dec 5, 2020 10:00AM New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
Nov 23, 2020 07:00PM Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
Nov 18, 2020 08:35AM Gilead Sciences' (GILD) Lenacapavir Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
Nov 18, 2020 08:35AM Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
Nov 15, 2020 05:30PM Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
Nov 5, 2020 09:00AM Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020
Oct 28, 2020 04:02PM Gilead Sciences Announces Fourth Quarter 2020 Dividend
Oct 23, 2020 09:15AM Gilead Sciences (GILD) Completes Acquisition of Immunomedics (IMMU)
Oct 23, 2020 09:15AM Gilead Sciences Completes Acquisition of Immunomedics, Inc.
Oct 22, 2020 04:09PM Gilead Sciences (GILD) Confirms FDA Approved its Antiviral Veklury for Treatment of COVID-19
Oct 22, 2020 04:02PM U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
Oct 22, 2020 12:23PM Gilead Sciences (GILD) Announces Anthony Welters to Board
Oct 22, 2020 12:15PM Anthony Welters Joins Gilead Sciences’ Board of Directors
Oct 21, 2020 07:05AM Gilead Sciences (GILD) Presents New Data Showing Biktarvy Effective for the Treatment of HIV in Black Americans
Oct 21, 2020 07:01AM Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans
Oct 19, 2020 08:40AM Gilead (GILD) Presents New Data from Antiviral Development Programs at IDWeek 2020
Oct 19, 2020 08:30AM Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020
Oct 16, 2020 07:29AM Gilead (GILD) Announces European CHMP Adopts Positive Opinion for Kite's KTE-X19 for the Treatment of R/R Mantle Cell Lymphoma
Oct 16, 2020 07:28AM European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Oct 14, 2020 04:01PM Gilead Sciences to Release Third Quarter 2020 Financial Results on Wednesday, October 28, 2020
Oct 14, 2020 08:33AM Gilead Sciences (GILD) Announces Expiration of HSR Waiting Period for Immunomedics (IMMU) Tender Offer
Oct 14, 2020 08:30AM Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for Immunomedics Tender Offer
Oct 8, 2020 05:15PM Gilead Sciences (GILD) Reports Final Results of NIAID ACTT-1 Trial Published in NEJM Expand Clinical Benefits of Veklury for Treatment of COVID-19
Oct 8, 2020 05:05PM Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment
Oct 5, 2020 06:27AM Gilead Sciences (GILD) Presents Biktarvy Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020
Oct 5, 2020 06:00AM Gilead Presents Biktarvy® Findings From Switch Studies & Analysis of Real-World BICSTaR Study At HIV Glasgow 2020
Sep 30, 2020 08:38AM Gilead Sciences (GILD) Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
Sep 30, 2020 08:37AM Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
Sep 17, 2020 01:44PM Eli Lilly (LLY) Said Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19
Sep 15, 2020 08:01AM Gilead Sciences (GILD) Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
Sep 15, 2020 08:00AM Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome
Sep 13, 2020 08:03PM Gilead Sciences (GILD) to Acquire Immunomedics (IMMU) for $21 Billion
Sep 13, 2020 03:00PM Gilead Sciences to Acquire Immunomedics
Sep 4, 2020 08:37AM Gilead's(GILD) Kite Submits sBLA to FDA for Yescarta in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Sep 4, 2020 08:30AM Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas
Aug 25, 2020 02:00AM Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress™ 2020
Aug 19, 2020 06:10AM Gilead Sciences (GILD) Receives CRL for Filgotinib for Treatment of Moderately to Severely Active Rheumatoid Arthritis
Aug 18, 2020 07:25PM Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Aug 11, 2020 08:14AM Gilead Sciences (GILD) Announces China National Medical Products Administration Approves Truvada for HIV Pre-Exposure Prophylaxis
Aug 11, 2020 08:11AM China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
Aug 10, 2020 11:00AM Gilead Sciences (GILD) Submits NDA to U.S. FDA for Veklury (Remdesivir) for Treatment of COVID-19
Aug 10, 2020 11:00AM Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
Aug 7, 2020 08:00AM Pfizer (PFE) Announces Agreement with Gilead (GILD) to Manufacture Remdesivir for Treatment of COVID-19
Jul 30, 2020 04:02PM Gilead Sciences Announces Third Quarter 2020 Dividend
View More Recent Stories View Older Stories